Abstract
Metilfenidat çocuklarda Dikkat Eksikliği Hiperaktivite Bozukluğu (DEHB)’ nun tedavisinde sıklıkla kullanılan bir farmakolojik ajandır.
Tedavi dozlarında oldukça güvenli bir ilaç olarak kabul edilir. Özellikle tedavinin ilk günlerinde klinik olarak anlamlı olmayan ve risk
taşımayan, hafif düzeyde kan basıncı değişiklikleri görülebilirken daha yüksek dozlarda ciddi kardiyak aritmilerinde içinde bulunduğu
önemli kardiyak yan etkilerin geliştiği bildirilmiştir. Yaşamsal önem teşkil eden yan etkiler oldukça nadir görülse bile, ilaç kullanımı
sırasında hekimlerde ciddi endişelere sebeb olabilmektedir. Bizde bu yazıda DEHB nedeni ile metilfenidat kullanan, Mobitz tip 1 AV
blok ile acile başvuran 8 yaşındaki erkek hastamızı literatüre katkı sağlamak amacıyla sunmak istedik.
( Sakarya Tıp Dergisi 2016, 6(4):231-234 )
References
- Refernas1. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther.2008; 30:942-57.
- Referans2. Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf. 1997; 17:143-8.
- Referans3. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000;39:15-25.
- Referans4. Cooper W. O., Habel L. A., Sox C. M., et al. ADHD drugs and serious cardiovascular events in children and young adults. The New England Journal of Medicine. 2011;365:1896–1904.
- Refernas5. Rosler M, Fischer R, Ammer R, Ose C, et al. A randomised, placebo-controlled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attention-deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259:120–9.
Abstract
Methylphenidate is a commonly used pharmacological agents in the treatment of pediatric patients with Attention Deficit Hyperactivity
Disorder (ADHD). It is considered to be a relatively safe drug in therapeutic doses. Especially in the early days of the treatment of
clinically non-significant risk free, mild blood pressure changes occur. Higher doses caused significant cardiac side effects have been
reported in which the serious cardiac arrhythmias. These side effects are rare life-threatening consequences. Therefore it raises serious
concerns in the physician during treatment. In this paper, we want to offer 8-year-old male patient who admitted to the emergency
Mobitz type 1 AV block associated with the use of methylphenidate in order to contribute to the literature.
( Sakarya Med J 2016, 6(4):231-234 ).
References
- Refernas1. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther.2008; 30:942-57.
- Referans2. Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf. 1997; 17:143-8.
- Referans3. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000;39:15-25.
- Referans4. Cooper W. O., Habel L. A., Sox C. M., et al. ADHD drugs and serious cardiovascular events in children and young adults. The New England Journal of Medicine. 2011;365:1896–1904.
- Refernas5. Rosler M, Fischer R, Ammer R, Ose C, et al. A randomised, placebo-controlled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attention-deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259:120–9.
Details
| Journal Section | Articles |
|---|---|
| Authors | |
| Publication Date | December 29, 2016 |
| Submission Date | October 6, 2017 |
| Published in Issue | Year 2016 Volume: 6 Issue: 4 |
The published articles in SMJ are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.